WUHU, China, Oct. 23, 2025 /PRNewswire/ — On October 21, the 2025 Chery International User Summit reached new heights as Malaysian pop star JeryL Lee made an elegant appearance at the Chery International User Carnival, arriving in the LEPAS L8 and delivering a stunning performance. Ybg. Mr. NG KAI SENG, Minister-Counsellor of the Embassy of Malaysia in China, also attended, witnessing LEPAS’s interpretation of Elegant Driving and a key moment in its global journey.

As one of Southeast Asia’s most acclaimed new-generation singers, JeryL Lee—with her pure voice and radiant image—perfectly embodies the LEPAS philosophy of “Drive Your Elegance.” During the Carnival Music Festival, she performed three of her hit songs, igniting the crowd and pushing the event to its climax. Music, technology, and mobility merged seamlessly, expressing LEPAS’s positioning as the “Preferred Brand for Elegant Mobility Life.” JeryL also visited the world’s first LEPAS Elegant Lifestyle House, experiencing the brand’s vision of being not only a mobility partner but also a symbol of urban elegance accompanying users in every moment.

Her exclusive ride—the LEPAS L8—captivated attention throughout the event. As LEPAS’s flagship model, it embodies the brand’s three core values: Leopard Aesthetics, Elegant Driving, and Exquisite Space. Inspired by the grace and strength of the leopard, the LEPAS L8 features dynamic body lines and signature lighting details that reflect the spirit of“Elegance is Power.”Inside, the skyline-inspired cabin merges refined materials with intelligent technology, creating a luxurious yet functional mobility space for global urban elites. With a wading depth of 600mm, the LEPAS L8 easily handles Southeast Asia’s frequent rain and flooding, offering confident, elegant travel across the region.

As Chery Group’s new energy brand, LEPAS is rapidly expanding in Southeast Asia under the global vision“In somewhere, For somewhere, Be somewhere.”On October 17, during the summit, LEPAS signed partnership agreements with five Indonesian dealerships. Going forward, LEPAS will continue to enhance its presence and deliver elegant, sustainable mobility solutions across Southeast Asia, reinforcing its position as the Preferred Brand for Elegant Mobility Life.

HONG KONG, Oct. 23, 2025 /PRNewswire/ — Recently, CaoCao Inc. (‘CaoCao’ or ‘Company’ , stock code: 2643.HK) released an overseas ride-hailing guide and launched overseas mobility services in multiple countries and regions. The service initially covers 10 popular tourist cities across 6 countries—Singapore, South Korea, Malaysia, Thailand, the Philippines, and Vietnam, as well as Hong Kong SAR. This means Chinese domestic users no longer need to download additional local ride-hailing apps; they can directly hail taxis overseas via the CaoCao mobility app, which significantly simplifies the overseas travel process.

Now, users only need to open the CaoCao mobility app and switch their location to the aforementioned service-supported countries and regions to enjoy “one-stop ride-hailing  freedom”. Take Singapore as an example: if users travel there for a winter vacation, all their local transportation needs, such as traveling between Changi Airport and hotels, visiting famous attractions like Merlion Park, or exploring Nanyang cuisine in Geylang, can be met through the CaoCao mobility.

According to the latest 2025/2026 Tourism Trends Report released by ITB CHINA, the number of outbound trips made by Chinese mainland residents exceeded 145 million in 2024, and the number of Chinese mainland residents traveling to destinations worldwide is expected to keep growing in 2025. Against this industry backdrop, the demand of domestic tourists for “convenient and localized” overseas mobility services has become increasingly prominent. Previously, Chinese tourists often encountered problems such as language barriers, incompatible payment methods, and unfamiliarity with operations when using local ride-hailing apps overseas. CaoCao Inc.’s overseas mobility service addresses these pain points precisely.

CaoCao stands as a pivotal element in Geely’s future mobility strategy. The company currently covers 163 cities across China, with an average of 38.1 million monthly active users (MAU). With over 37,000 purpose-built vehicles in operation across more than 30 cities nationwide, it has become the biggest technology-driven mobility platform listed on the Hong Kong Stock Exchange. The newly launched overseas mobility service features a unified Chinese interface and real-time Chinese online translation. It also enables RMB mobile payment methods aligned with domestic users’ routines, so there’s no need for extra foreign currency exchange or linking overseas payment tools to the app. As a leading ride-hailing app in China, its branded services have further upgraded the ride-hailing experience abroad.

As the international market thrives, CaoCao Inc. has rolled out its overseas mobility service first in cities like Hong Kong SAR, Singapore, Seoul, Busan, Jeju, Kuala Lumpur, Kota Kinabalu, Bangkok, Ho Chi Minh City and Pasay. It also plans to expand further into popular destinations worldwide. The convenience of “one-stop” ride-hailing service, together with the company’s rich experience of mobility services in China, not only provide Chinese travelers with worry-free and secure international mobility services, but also allow more local residents to access and experience the convenience offered by this Chinese mobility app.

 

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM) that, for the first time, include the use of Telix’s investigational PET^[1] agent, TLX250-CDx (Zircaix®^[2], ⁸⁹Zr-DFO-girentuximab), for molecular imaging of renal masses.

Published on the SNMMI website^[3] and in The Journal of Nuclear Medicine^[4], the guideline panel^[5], comprising internationally renowned and multidisciplinary expert key opinion leaders, concludes that “the emerging use of molecular imaging for risk stratification of indeterminate renal masses offers the opportunity to more effectively characterize such lesions and optimize patient management decisions”.

The panel asserts that antibody-based radiotracers exhibit lower renal clearance, thereby improving visualization of renal masses. It emphasizes that TLX250-CDx PET “appears to be a well-tolerated and accurate method for non-invasive identification of ccRCC^[6]” and notes by contrast, the high renal excretion with ¹⁸F-FDG PET, which obscures accurate lesion detection.

The panel references data from Telix’s pivotal Phase 3 ZIRCON trial^[7], which met all primary and secondary endpoints, demonstrating a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions^[8]. TLX250-CDx works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on >95% of ccRCC cells^[9], to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.

Professor Brian Shuch, MD, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA Institute of Urologic Oncology and guideline author, commented, “The recognition of ⁸⁹Zr-girentuximab PET in the SNMMI/EANM/ACNM clinical guidelines reflects a shift toward precision medicine in renal cancer, providing clinicians with a more accurate tool for diagnosis to guide optimal, individualized treatment planning for patients.”

Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, added, “The inclusion of TLX250-CDx PET imaging for the first time in SNMMI/EANM/ACNM guidelines is an important development for Telix and will help raise awareness of this breakthrough precision diagnostic. Subject to regulatory approval, endorsement by this expert global multidisciplinary panel will help to drive adoption and implementation into clinical workflows, supporting clinical utility and enhancing decision-making to improve patient outcomes.”

SNMMI, EANM and ACNM periodically define new procedure standards/guidelines to help advance the science of nuclear medicine and to improve the quality of service to patients. Each standard/guideline, representing a policy statement by these groups undergoes a thorough consensus process in which it has been subjected to extensive review.

About TLX250-CDx

TLX250-CDx is an investigational PET agent that is under development for the diagnosis and characterization of ccRCC. Telix’s pivotal Phase 3 ZIRCON trial evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% PPV for ccRCC across three independent radiology readers. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC.

For more on TLX250-CDx and Telix’s theranostic kidney cancer program, click here.
TLX250-CDx has not received a marketing authorization in any jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA^[10].

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
Eliza@schleifsteinpr.com

Legal Notices
Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

[1] Positron emission tomography.
[2] Brand name subject to final regulatory approval.
[3] https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2025/SNMMI_EANM _ACNM_Renal_Masses-Final%20JNM%20sumbission.pdf
[4] SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization (October 2025), available at: https://jnm.snmjournals.org/content/early/2025/10/09/jnumed.125.271332.abstract
[5] Steven P. Rowe, Brian M. Shuch, Mark W. Ball, Axel Bex, Mehrbod S. Javadi, Alan Klitzke, Karolien Goffin, Peter Mulders, Neeta Pandit-Taskar, Ashwin Singh Parihar, Benjamin L. Viglianti, Michael A. Gorin, and Ken Herrmann.
[6] Clear cell renal cell carcinoma, the most common and one of the most aggressive subtypes of kidney cancer.
[7] ClinicalTrials.gov ID: NCT03849118.
[8] Telix ASX disclosures 7 November 2022. Shuch et al. Lancet Oncology. 2024.
[9] Stillebroer et al. Eur Urol. 2010.
[10] Telix ASX disclosure 21 March 2025.

With a strong track record across APAC, Francis Wan’s appointment marks a powerful acceleration of Medison’s growth in the region

ZUG, Switzerland, Oct. 23, 2025 /PRNewswire/ — Medison, the creator of a first-of-its-kind unified global commercialization platform for breakthrough therapies, today announced the appointment of Francis Wan as VP, GM Asia Pacific (APAC) and member of the company’s Global Leadership Team.

Francis will lead Medison’s strategy and operations across the APAC region, a critical growth area for the company’s platform. With more than 20 years of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. His expertise in rare disease and oncology, together with his extensive experience in China’s healthcare landscape, adds a vital dimension to Medison’s strategy for the region.

“Across APAC, breakthrough therapies are still out of reach for many patients, leaving a vast and diverse population with significant unmet needs,” said Francis Wan. “Through Medison’s global commercialization platform, we have a unique opportunity to change this reality and expand access to breakthrough therapies. Having spent much of my career in China and across APAC, I understand firsthand how essential it is to deliver sustainable solutions and enable faster access for patients with rare and severe diseases.”

“Medison was founded on the belief that every patient, no matter where they live, deserves timely access to breakthrough therapies,” said Meir Jakobsohn, Founder and Executive Chairman of Medison. “Francis’s appointment reflects our continued investment in APAC and marks an important step in accelerating additional growth in the region, a region with enormous need and opportunity.”

“Francis joining Medison is another important milestone in our global growth journey,” said Gil Gurfinkel, CEO of Medison. “With his appointment, we continue to advance toward completing our expansion roadmap and building a world leader and the best commercialization company for international markets. Francis’s extensive experience with healthcare systems and his proven record of creating access and commercial success in China and across APAC will strengthen our ability to accelerate access to life-changing therapies and deepen our partnerships in the region and on a global scale.”

“Francis brings outstanding expertise and a proven track record in establishing and scaling biopharma operations in China and the broader APAC region,” said Victor Papamoniodis, Chief Commercial Officer at Medison. “His leadership will be instrumental in scaling our platform and expanding patient access to breakthrough therapies in APAC.”

About Medison
At Medison, we are addressing one of the pharma industry’s most pressing challenges: enabling access to breakthrough therapies for patients with severe and rare diseases in international markets where traditional commercialization models fall short. 

As the creator and leader of the global partnership category, we have built a first-of-its-kind unified commercialization platform that enables biotechs to effectively plan, optimize and launch their therapies on a global scale. 

With a strong leadership team and a proven track record, we are the partner of choice for innovative biotech companies seeking to expand beyond the US, Western Europe and Japan into regions where most of the world’s population resides. Our affiliate-like model integrates commercial, medical and operational capabilities across diverse geographies, accelerating access and delivering life-changing treatments to more patients, faster. 

Medison is on a mission to ensure that every patient, regardless of where they live, has the opportunity to benefit from breakthrough therapies. 

For more information, please visit https://www.medisonpharma.com/

Contact:
Margo Corn Ladani 
Senior Manager, Global Communications 
T:  +972 52 6606710
E: MargoC@medisonpharma.com

 

• Prestigious peer-review validates HCB101’s differentiated mechanism and translational strength.
• Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono)

TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology (SCI Impact Factor 40.4; for reference, leading journals in the field of immuno-oncology include Journal of Clinical Oncology (impact factor 41.9), The Lancet Oncology (35.9), and Nature Cancer (28.5)).

The publication, titled “HCB101: A Novel Potent Ligand-Trap Fc-fusion Protein Targeting the CD47-SIRPα Pathway with High Safety and Preclinical Efficacy for Hematological and Solid Tumors,” describes the rational protein engineering that enabled HCB101 to restore macrophage-mediated phagocytosis and bridge innate and adaptive immune responses while reducing red blood cell binding. In preclinical studies, HCB101 showed broad activity across more than 80 xenograft and PDX tumor animal models with a safety profile that differs from first- and second-generation CD47-targeting agents.

Notably, a US competitor focusing on CD47/SIRPα published findings in JHO in November 2020, reporting on a third-generation anti-CD47–SIRPα therapy. This underscores the journal’s strong recognition within the field. The continued publication of anti-CD47 biologics in JHO highlights both the scientific importance of ongoing advancements and the journal’s role as a leading international platform for preclinical and translational research on anti-CD47 therapies.

“Publication in the Journal of Hematology & Oncology affirms the scientific rigor and innovation behind HCB101 and emphasizes its differentiated preclinical foundation,” said Scott Liu, PhD, Chairman, CEO, and Founder of HanchorBio. “Importantly, these insights are being directly translated into clinical studies: combined with standard-of-care, HCB101 has demonstrated a clear dose-dependent efficacy profile in 2L gastric cancer, culminating in a nearly 90% partial response rate at 5.12 and 8.0 mg/kg. In parallel, we have now escalated monotherapy dosing to 30 mg/kg without safety concerns. These milestones highlight HCB101’s potential to serve as a backbone immunotherapy across solid tumors and hematologic malignancies and lay the groundwork for expanding into autoimmune indications where CD47-SIRPα biology is also potentially useful in creating a new B-cell depletion therapy.”

Clinical Progress Strengthens Differentiated Best-in-Class Profile
HCB101 is currently being evaluated in multinational Phase 1 and Phase 1b/2a trials:

• Monotherapy (HCB101-101, NCT05892718):
  The Safety Review Committee (SRC) has reviewed the safety data up to 30 mg/kg weekly and found no dose-limiting toxicities, confirming a wide therapeutic window. Early signs of efficacy included two confirmed partial responses (PRs) in head and neck squamous cell carcinoma and marginal zone lymphoma, along with stable disease (SD) in nine patients, including over 40 weeks of disease control in platinum-resistant ovarian cancer.

• Combination (HCB101-201, NCT06771622):
  In the triplet regimen for 2L-gastric cancer (HCB101 + ramucirumab + paclitaxel), emerging activity was first observed at 2.56 mg/kg, where evaluable patients achieved SD with modest tumor shrinkage, averaging a 6% reduction in tumor size in the dose cohort. At 5.12 mg/kg, all three evaluable patients achieved confirmed PRs (33%–46% tumor reductions). At 8.0 mg/kg, all three evaluable patients have now achieved confirmed PRs (tumor shrinkage up to -78%) after extended follow-up. Together, these results represent a nearly 90% confirmed response rate (6 of 7 patients) at ≥ 5.12 mg/kg dose level — a striking outcome in a setting where the typical overall response rate (ORR) for the SOC is only 26.5%.

“The data now published in JHO validate the design strategy that made HCB101 possible – balancing high efficacy with a clean safety margin where earlier CD47-targeting agents failed,” added Wenwu Zhai, PhD, Chief Scientific Officer of HanchorBio. “Seeing those preclinical insights translate into durable monotherapy activity and remarkable combination dose-dependent responses in gastric cancer provides confidence not only for oncology but also for new areas such as autoimmunity. HCB101’s differentiated mechanism and safety profile open the door to rational combinations and next-generation applications well beyond cancer.”

About HCB101: A Differentiated CD47-SIPRα Blockade
HCB101 is a 3.5^th-generation, affinity-optimized SIRPα-Fc fusion protein with intact IgG4 effector function, developed using HanchorBio’s proprietary FBDB™ platform. Engineered for selective CD47 blinding on tumors with low affinity for red blood cells, HCB101 avoids the hematologic toxicities commonly associated with anti-CD47 monoclonal antibodies, while preserving strong antibody-dependent cellular phagocytosis (ADCP) and innate-to-adaptive immune bridging.

Key Differentiators of HCB101:

• Enhanced safety: Low RBC binding minimizes anemia and thrombocytopenia risk.
• Robust immune activation: Engineered to enhance ADCP and innate-to-adaptive bridging.
• Broad tumor applicability: Demonstrated activity in >80 PDX/CDX preclinical models.
• Clinical translation: Early efficacy as monotherapy with durable disease control, and 100% ORR and disease control rate (DCR) at the middle dose cohort in combination with standard-of-care for 2L-gastric cancer.

About HanchorBio

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx), a global biotechnology company specializing in immuno-oncology, is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and international development, aiming to rewrite cancer therapies. Committed to reactivating the immune system to fight diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables the development of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: www.HanchorBio.com

SHANGHAI, Oct. 23, 2025 /PRNewswire/ — Today, JCET Group (SSE: 600584), a leading global provider of integrated circuit (IC) back-end manufacturing and technology services, released its financial results for the third quarter of 2025. JCET reported record Q3 revenue of RMB 10.06 billion, up 8.6% quarter-on-quarter, marking the highest third-quarter revenue in the company’s history. Net profit attributable to shareholders reached RMB 480 million, an increase of 80.6% from the previous quarter, while profit before tax (PBT) was up 29.3% year-on-year to RMB 610 million.

For the first nine months of 2025, JCET generated RMB 28.67 billion in revenue, up 14.8% year-on-year, setting a new record for the same period. Net profit attributable to shareholders totaled RMB 950 million.

In 2025, JCET accelerated efforts to upgrade advanced packaging capabilities and expand production capacity, while driving application-focused innovation and strengthening both global and local customer engagement. As a result, capacity utilization rose steadily from Q1 to Q3, reaching near-full levels across key product lines, including wafer-level packaging, power device packaging, and power management chip packaging.

Several business segments delivered strong year-on-year revenue growth in Q3 YTD 2025. Revenue from computing electronics, industrial and medical electronics, and automotive electronics rose by 69.5%, 40.7% and 31.3%, respectively. JCET’s transformation continues to be driven by investment in high value-added areas, new product ramp-ups, and the expansion of mass production. With demand rebounding and utilization rates rising, the company plans to further optimize its product mix, prioritize capacity for high-margin products, and enhance overall profitability.

In the first three quarters of 2025, JCET significantly increased its R&D investment, with expenses rising 24.7% year-on-year to RMB 1.54 billion. The company achieved breakthrough progress in several critical technology areas, including co-packaged optics (CPO), glass substrates, large-format fcBGA packaging, and high-density system-in-package (SiP) solutions. In parallel, JCET continues to attract top global talent and strengthen its R&D capabilities, further solidifying the foundation for long-term innovation and sustainable growth.

For more information, please refer to the JCET Q3 2025 Report. 

About JCET Group

JCET Group is a global leader in integrated circuit back-end manufacturing and technology services. We provide comprehensive turnkey solutions, including semiconductor package integration design, wafer probing, bumping, assembly, final testing, and global drop shipments.

Utilizing advanced wafer-level packaging, 2.5D/3D packaging, System-in-Package solutions, and reliable flip chip and wire bonding technologies, we support a wide range of applications, including automotive, artificial intelligence, high-performance computing, storage, communication, smart devices, industrial and medical sectors, and power and energy. With cutting-edge R&D centers in China and Korea, and manufacturing facilities across China, Korea, and Singapore, we deliver efficient supply chain solutions and maintain close collaboration with our global customers.

Engineers to oversee tech transfers, support manufacturing partnerships, and co-develop AI-driven solutions with customers

SINGAPORE, Oct. 23, 2025 /PRNewswire/ — Switzerland’s Enclustra GmbH today launched Enclustra Asia, its regional headquarters in Singapore, marking a strategic expansion into Southeast Asia’s advanced manufacturing and innovation landscape with an eye to talent acquisition.

The new Asian HQ will recruit about 100 design engineers, sales, and marketing professionals to oversee technology transfers from Enclustra’s Zurich headquarters, coordinate partnerships with local manufacturers, and collaborate closely with customers to deliver next-generation AI-enabled solutions tailored for commercial applications.

Recently, the Swiss Tech Company, a global leader in field-programmable gate array (FPGA) solutions, launched its new Physical AI-Machine Learning Technology Line in collaboration with SiMa.ai.

The Singapore-based engineers will play a key role in localising Enclustra’s FPGA-based technologies, adapting high-performance computing platforms for regional needs, and accelerating product development cycles. Their work will also support joint innovation initiatives with academic and industry partners, reinforcing Singapore’s position as a hub for deep-tech talent and smart manufacturing.

This talent acquisition is intended to support the estimated US$100 million in contracts that Enclustra plans to outsource annually to Singapore’s manufacturing ecosystem within the next three to four years.

The key thrusts of Enclustra’s strategic moves are:

• Establishment of Enclustra Asia, with Singapore designated as its Operations Centre of Excellence. The new entity will serve as a hub for sales, engineering services, regional manufacturing, and the design and development of FPGA-based solutions.
• Collaboration with Singapore universities with a view to setting up innovation labs. Discussions are currently underway with the Nanyang Technological University (NTU) to launch several projects.
• Design transfer coordination from Enclustra’s global headquarters in Zurich to appointed contract manufacturers in Singapore. These partnerships are expected to contribute approximately US$100 million annually to Singapore’s export ecosystem by FY2026, with a projected compound annual growth rate of 40% thereafter.

Enclustra planned for its Asia Pacific expansion in 2020 as part of its five-year roadmap. Following the setting up of its US Office in San Diego in 2023, plans were underway for the Singapore operations. A key driving force behind the choice of Singapore is its strong pool of FPGA engineering talent, particularly in sectors such as semiconductors, embedded systems, and advanced manufacturing.

Enclustra CEO Phillip Bächtold said, “Enclustra’s purpose has always been clear: to enable innovation that is life-saving, life-changing, and dream-making in terms of the impact on human lives. Our FPGA technology empowers customers to shape the future, whether that means developing smarter medical devices, enhancing safer autonomous systems, or achieving faster and more efficient industrial control.

Our expansion to Singapore and collaboration with Singapore universities mark the next step in that journey. It’s about putting the full power of reconfigurable computing closer to our customers, so they can move from concept to breakthrough faster than ever. We’re not just advancing hardware; we’re enabling the ideas that define tomorrow.”

Economic Development Board Executive Vice President Ms Cindy Koh said, “Singapore offers a vibrant, advanced manufacturing ecosystem for global companies looking to expand into Asia and scale innovative solutions to international markets. Enclustra’s latest investment brings new FPGA-based solutions that will strengthen Singapore’s advanced manufacturing sector, creating more partnership opportunities for our local enterprises and adding 100 skilled roles here.”

Switzerland’s Ambassador to Singapore, H.E. Mr Frank Grütter, who was present at the event, said: “Enclustra’s investment is more than just an expansion – it also strengthens the partnership between Switzerland and Singapore.

“I am convinced that it will accelerate the development of the advanced electronics sector in this region and reinforce Switzerland’s reputation for precision, reliability and innovation – characteristics that we share with Singapore,” he said.

About Enclustra GmbH

Enclustra is an innovative, dynamic, and growing company specialising in FPGA design, with headquarters in Zurich, Switzerland, and subsidiaries in Germany, France, the USA, and China. As a leader in FPGA design and development, Enclustra offers a product portfolio of FPGA-based electronic modules and FPGA-optimised IP solutions for industrial customers and R&D organisations. In parallel, Enclustra provides leading engineering services in FPGA system design, covering the entire spectrum of FPGA-based system development, from high-speed hardware and HDL firmware to embedded software, as well as from system design, specification, and implementation to prototyping. Leveraging our expertise in cutting-edge FPGA technology and diverse application knowledge, Enclustra delivers high-performance solutions across various industries, minimising development effort and accelerating your time-to-market.